• Equillium disclosed new preclinical findings for EQ504, an ulcerative colitis program, slated for presentation Oct. 6 at La Jolla Immunology.
• Results have not yet been presented; the data will be shown in a conference poster session.
• Study indicated EQ504 helped preserve intestinal barrier function while dampening inflammation in a lab-based co-culture model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Equillium Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061605PRIMZONEFULLFEED9840825) on October 06, 2026, and is solely responsible for the information contained therein.